Effectiveness and Safety of 18F-FDG PET in the Evaluation of Dementia: A Review of the Recent Literature

Journal of Nuclear Medicine

David S.W. Djang¹  Yoshimi Anzai¹  Karl Herholz¹  Satoshi Minoshima¹  Nicolaas I. Bohnen¹ 

关键词: Alzheimer disease;    diagnosis;    dementia;    fluorodeoxyglucose;    PET;    physician confidence;    prognosis;   

DOI  :  10.2967/jnumed.111.096578

学科分类：医学（综合）

来源: Society of Nuclear Medicine

【 摘 要 】

Imaging that can detect pathophysiologic change in the brain holds great promise for diagnostic assessment of patients with Alzheimer disease (AD) and dementia. Although a previous metaanalysis centering on literature from 1990 to 2000 showed a summary accuracy of 86% for 18F-FDG PET for AD diagnosis, the clinical value was considered uncertain because of methodologic shortcomings. Review of the recent literature since 2000 demonstrates that the evidence for 18F-FDG PET in assessment of dementia has increased with new studies that include autopsy confirmation, wide-diagnostic-spectrum recruitment in primary care settings, historical and prospective cohort studies, and multicenter data analyses. These data support the role of 18F-FDG PET as an effective and useful adjunct to other diagnostic information in the assessment of patients with symptoms of dementia. Findings are in line with recently revised diagnostic criteria of AD that for the first time recognize the unique role of biomarker evidence in disease definition.

【 授权许可】

Unknown